Insider Trading Alert - BSTC, WRI And SYNA Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 1, 2015, 100 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $181.50 to $4,800,000.00.

Highlighted Stocks Traded by Insiders:

BioSpecifics Technologies (BSTC) - FREE Research Report

Gitman Paul, who is Director at BioSpecifics Technologies, sold 15,000 shares at $46.76 on June 1, 2015. Following this transaction, the Director owned 51,825 shares meaning that the stake was reduced by 22.45% with the 15,000-share transaction.

The shares most recently traded at $47.49, up $0.73, or 1.54% since the insider transaction. Historical insider transactions for BioSpecifics Technologies go as follows:

  • 4-Week # shares sold: 2,950
  • 12-Week # shares sold: 2,950
  • 24-Week # shares sold: 2,950

The average volume for BioSpecifics Technologies has been 34,500 shares per day over the past 30 days. BioSpecifics Technologies has a market cap of $321.1 million and is part of the health care sector and drugs industry. Shares are up 23.36% year-to-date as of the close of trading on Monday.

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company has a P/E ratio of 54.8. Currently, there are no analysts who rate BioSpecifics Technologies a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BSTC - FREE

TheStreet Quant Ratings rates BioSpecifics Technologies as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, solid stock price performance and compelling growth in net income. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full BioSpecifics Technologies Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Weingarten Realty Investors (WRI) - FREE Research Report

Shapiro Marc J, who is Director at Weingarten Realty Investors, bought 20,000 shares at $33.95 on June 1, 2015. Following this transaction, the Director owned 112,587 shares meaning that the stake was boosted by 21.6% with the 20,000-share transaction.

The shares most recently traded at $34.27, up $0.32, or 0.93% since the insider transaction. Historical insider transactions for Weingarten Realty Investors go as follows:

  • 4-Week # shares sold: 20,000
  • 12-Week # shares bought: 2,000
  • 12-Week # shares sold: 20,000
  • 24-Week # shares bought: 2,000
  • 24-Week # shares sold: 49,203

The average volume for Weingarten Realty Investors has been 615,700 shares per day over the past 30 days. Weingarten Realty Investors has a market cap of $4.2 billion and is part of the financial sector and real estate industry. Shares are down 1.17% year-to-date as of the close of trading on Monday.

Weingarten Realty Investors is a publically owned equity real estate investment trust. The firm invests in the real estate markets of United States. The firm engages in ownership, management, acquisition, development and redevelopment. The stock currently has a dividend yield of 4.09%. The company has a P/E ratio of 16.1. Currently, there is 1 analyst who rates Weingarten Realty Investors a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WRI - FREE

TheStreet Quant Ratings rates Weingarten Realty Investors as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, notable return on equity, expanding profit margins, good cash flow from operations and impressive record of earnings per share growth. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Weingarten Realty Investors Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Synaptics (SYNA) - FREE Research Report

Sewell Bretton, who is Officer at Synaptics, sold 5,475 shares at $99.88 on June 1, 2015. Following this transaction, the Officer owned 8,858 shares meaning that the stake was reduced by 38.2% with the 5,475-share transaction.

The shares most recently traded at $100.05, up $0.17, or 0.17% since the insider transaction. Historical insider transactions for Synaptics go as follows:

  • 4-Week # shares sold: 1,724
  • 12-Week # shares sold: 4,958
  • 24-Week # shares sold: 15,739

The average volume for Synaptics has been 741,900 shares per day over the past 30 days. Synaptics has a market cap of $3.7 billion and is part of the technology sector and computer software & services industry. Shares are up 45.15% year-to-date as of the close of trading on Monday.

Synaptics Incorporated develops, markets, and sells custom-designed human interface solutions for electronic devices and products primarily in China, South Korea, Taiwan, the United States, Japan, and other countries. The company has a P/E ratio of 33.5. Currently, there are 7 analysts who rate Synaptics a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SYNA - FREE

TheStreet Quant Ratings rates Synaptics as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, compelling growth in net income and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Synaptics Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Biotechs Among 5 Stocks Setting Up for Major Breakouts

Biotechs Among 5 Stocks Setting Up for Major Breakouts

7 Stocks Making Big Moves on Unusual Volume

7 Stocks Making Big Moves on Unusual Volume

7 Stocks Breaking Out on Big Volume

7 Stocks Breaking Out on Big Volume

Insider Trading Alert - USCR, BSTC And OCN Traded By Insiders

Insider Trading Alert - USCR, BSTC And OCN Traded By Insiders

Insider Trading Alert - BSTC, TWO And CTRE Traded By Insiders

Insider Trading Alert - BSTC, TWO And CTRE Traded By Insiders